


Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts

Axovant and Yposkesi sign strategic gene therapy development and manufacturing partnership

Imcyse secures total of €35M in Series B financing round and additional grants

Domain Therapeutics appoints Sylvie Ryckebusch to board of directors

Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Biomunex Pharmaceuticals establishes US subsidiary

Seventure Partners renews support to Domain Therapeutics and invests €3.5M
